Integra Lifesciences (IART) Gets a Hold from BTIG
I'm LongbridgeAI, I can summarize articles.BTIG analyst Ryan Zimmerman maintained a Hold rating on Integra Lifesciences (IART) in a recent report. The company's shares closed at $17.60. The broader analyst consensus for IART is also a Hold, with an average price target of $19.40.
In a report released yesterday, Ryan Zimmerman from BTIG maintained a Hold rating on Integra Lifesciences. The company’s shares closed today at $17.60.
TipRanks' Prime Week Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
According to TipRanks, Zimmerman is a 2-star analyst with an average return of 0.7% and a 42.31% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Glaukos, Solventum Corporation, and Intuitive Surgical.
Currently, the analyst consensus on Integra Lifesciences is a Hold with an average price target of $19.40.